Engineered bacterial therapies that target the tumor immune landscape offer a new class of cancer immunotherapy. Salmonella enterica and Listeria monocytogenes are two species of bacteria that have been engineered to specifically target tumors and serve as delivery vessels for immunotherapies. Therapeutic bacteria have been engineered to deliver cytokines, gene silencing shRNA, and tumor associated antigens that increase immune activation. Bacterial therapies stimulate both the innate and adaptive immune system, change the immune dynamics of the tumor microenvironment, and offer unique strategies for targeting tumors. Bacteria have innate adjuvant properties, which enable both the delivered molecules and the bacteria themselves to stimulate immune responses. Bacterial immunotherapies that deliver cytokines and tumor-associated antigens have demonstrated clinical efficacy. Harnessing the diverse set of mechanisms that Salmonella and Listeria use to alter the tumor-immune landscape has the potential to generate many new and effective immunotherapies.

针对肿瘤免疫景观的工程细菌疗法提供了一类新的癌症免疫疗法。肠道沙门氏菌和单核细胞增生李斯特菌是两种经过改造专门针对肿瘤并充当免疫疗法输送容器的细菌。治疗性细菌已被设计用于传递细胞因子、基因沉默 shRNA 和增加免疫激活的肿瘤相关抗原。细菌疗法可刺激先天性和适应性免疫系统，改变肿瘤微环境的免疫动力学，并提供针对肿瘤的独特策略。细菌具有先天的佐剂特性，这使得传递的分子和细菌本身都能刺激免疫反应。递送细胞因子和肿瘤相关抗原的细菌免疫疗法已证明具有临床疗效。